Biohaven利用抗体药物结合物组合的早期数据

2025-12-12 03:56

Biohaven (BHVN) is up ~8% in Thursday trading after reporting phase 1 data on a combination of its Trop2 antibody drug conjugate BHV-1510 with Regeneron Pharmaceuticals' (REGN) Libtayo (cemiplimab) across several tumor types.
Enrolled patients had prior treatment, mostly with PD-L1 inhibitors. Data showed that among the 23 efficacy evaluable patients, treatment with BHV-1510 2.5 mg/kg plus Libtayo every three weeks led to an overall confirmed objective response rate of 52%. The rates were 42.9% in non-small cell lung cancer, 66.7% in endometrial cancer, and 50% in urothelial cancer.
Biohaven noted that no cases of interstitial lung disease were observed, a potential safety differentiating factor for BHV-1510 compared to other Trop2 ADCs. About 23% of patients experienced Grade 3 or higher oral mucositis/stomatitis toxicity, though this is a known class effect.
Results were presented at the 2025 European Society for Medical Oncology Immuno-Oncology Congress.

More on Biohaven